HPTN Publications

Khoza MN, Delany-Moretlwe S, Scorgie F, Hove J, Selin A, Imrie J, et al., Imrie J, Twine R, Kahn K, Pettifor A, MacPhail C . Men’s perspectives on the impact of female-directed cash transfers on gender relations: Findings from the HPTN 068 qualitative study. PLoS One. 2018, 13: e0207654

Brief Report: How Do We Reach Men? Offering HIV Testing in Evenings and Weekends in the HPTN 071 (PopART) Community-Based Trial in South Africa. 2023

Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis. 2023

The impact of a combined TB/HIV intervention on the incidence of TB infection among adolescents and young adults in the HPTN 071 (PopART) trial communities in Zambia and South Africa. PLoS Med. 2023, 3

An Exploration of Geographic Access to Substance Use Treatment Programs and Violence Against Women. J Interpers Violence.

Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis. 2023

Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial. 2025

1. Edupuganti E, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Acker, Edupuganti E, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Sobieszczyk M, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD . Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092). Lancet HIV. 2025, 12